Blueprint Medicines Corp’s recent filing unveils that its Director Albers Jeffrey W. unloaded Company’s shares for reported $0.51 million on May 27 ’25. In the deal valued at $101.14 per share,5,000 shares were sold. As a result of this transaction, Albers Jeffrey W. now holds 146,630 shares worth roughly $18.74 million.
Then, Albers Jeffrey W. bought 5,000 shares, generating $505,686 in total proceeds.
Before that, Rossi Christina sold 2,274 shares. Blueprint Medicines Corp shares valued at $228,557 were divested by the CHIEF OPERATING OFFICER at a price of $100.51 per share. As a result of the transaction, Rossi Christina now holds 64,718 shares, worth roughly $8.27 million.
Wedbush downgraded its Blueprint Medicines Corp [BPMC] rating to a Neutral from a an Outperform in a research note published recently. Wolfe Research began covering BPMC with “an Outperform” recommendation on March 18, 2025. Jefferies started covering the stock on March 17, 2025. It rated BPMC as “a Buy”.
Price Performance Review of BPMC
On Monday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 26.09% to $127.79. Over the last five days, the stock has gained 25.90%. Blueprint Medicines Corp shares have risen nearly 46.51% since the year began. Nevertheless, the stocks have risen 27.07% over the past one year. While a 52-week high of $121.90 was reached on 06/02/25, a 52-week low of $73.04 was recorded on 04/09/25. SMA at 50 days reached $92.81, while 200 days put it at $93.63.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 127.43, which if violated will result in even more drops to 127.07. On the upside, there is a resistance level at 128.15. A further resistance level may holdings at 128.51. The Relative Strength Index (RSI) on the 14-day chart is 76.54, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 8.36, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 1.07%. Stochastics %K at 92.36% indicates the stock is a selling.
The most recent change occurred on March 07, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $150 price target.
